



Joseph B. Kelley

Vice President
Government and Public Affairs

Eli Lilly and Company
555 Twelfth Street, NW
Washington, DC 20004 U.S.A.
Phone 202 434 1034 Fax 202 393 7960

E-Mail jbkelley@lilly.com

September 21, 2015

The Honorable Roger Wicker
United States Senate
555 Dirksen Senate Office Building
Washington, DC 20510

Dear Senator Wicker:

Eli Lilly and Company (Lilly), a global innovation-driven pharmaceutical and biotechnology corporation and leader in the field of Alzheimer's development, supports your effort in releasing the Ensuring Useful Research Expenditures is Key for Alzheimer's (EUREKA) Act Discussion Draft.

The EUREKA Act authorizes \$10 million a year for five years to award the winning submissions of Alzheimer's prize-competitions. In collaboration with an advisory council of experts, the NIH would lead the creation of the competition by establishing specific challenges, desired outcomes, and eligibility and evaluation metrics to ultimately award prizes to winning entrants.

Alzheimer's is the most expensive disease in the nation according to an NIH-funded study in the New England Journal of Medicine, with total costs of \$226 billion in 2015 estimated to rise to over \$1 trillion in 2050. The EUREKA Act's creation of an Alzheimer's prize competition is a promising tool to leverage scarce public resources to incentivize the development of treatments and cures, and stop the trajectory of this devastating disease.

Though we applaud a prize program, we also believe priority must be placed on policy analysis and public comments on broader system solutions and the overall structure of NIH private-public partnerships. We appreciate your leadership on this issue and look forward to working with you as the legislative process moves forward.

Sincerely,